Skip to Content

How You Can Help


Funds raised by Sprint for Life are put to work finding new and innovative ways of diagnosing, treating and managing ovarian cancer.  Each year, one or two $50,000 awards are given to MD Anderson faculty members to pursue specific research programs, with the combined goal of eliminating ovarian cancer. 


Pratip Bhattacharya, Ph.D.

Metabolic Imaging of ovarian cancer


Kelsey Mathieu, Ph.D.
Early detection ovarian cancer through nanomagnetic relaxometry

Yunfei Wen, Ph.D.
Promoting autophagic catabolism in chemoresistant ovarian cancer


George A. Calin, MD, Ph.D.
Combinatorial therapy for ovarian cancer

Prahlad Ram, Ph.D.
MicroRNA biomarkers and therapy in ovarian cancer


Alpa M. Nick, M.D.
Circulating tumor cells in ovarian cancer

Yuexin Liu, Ph.D.
Predicting therapy response in ovarian cancer


Wei Zhang, Ph.D.
MicroRNA therapy in ovarian cancer

Lois Ramondetta, M.D.
Targeting stress factors in ovarian cancer


Kathleen Schmeler, MD
Inherited and sporadic BRCA alterations in ovarian cancer

Vahid Afshar-Kharghan, M.D.
The role of complement pathway in ovarian cancer


Kwong K. Wong, Ph.D.
Understanding the molecular changes in cells that cause a rare ovarian cancer type: low grade serous carcinoma


Bulent Ozpolat, M.D., Ph.D.
Tumor-targeting siRNA – nanovectors for novel molecular therapy of metastatic ovarian cancer


Bryan Hennessy, M.D.
Proteomics to find markers of chemotherapy resistance in ovarian cancer


Michael Frumovitz, M.D., M.P.H.
The study of quality of life in women receiving second-line chemotherapy for recurrent ovarian cancer


Robert Luo, M.D., Ph.D. 
Evaluating tumor suppressor genes and apoptosis-independent autophagic cell death in ovarian cancer cells


Lois Ramondetta, M.D.
Evaluating the role of spirituality in coping with and surviving ovarian cancer

Judith Ann Smith, Pharm.D., FCCP, BCOP
Evaluating the possible ways to reverse drug resistance during treatment of ovarian cancer


Anil Sood, M.D.
How the neuroendocrine system regulates growth factors in ovarian cancer patients

Charlotte Sun, Dr.P.H., M.P.H.
Evaluating quality of life of patients receiving high dose chemotherapy for ovarian cancer


Diane Bodurka, M.D. 
Evaluating the preferences of toxicities for ovarian cancer patients on chemotherapy

Rosemarie Schmandt, Ph.D.
The study of genetic alterations in a specific class of molecules known as kinases, that are frequently observed in the development of ovarian cancer tumors

© 2015 The University of Texas MD Anderson Cancer Center